Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Feb 28, 2008; 14(8): 1268-1273
Published online Feb 28, 2008. doi: 10.3748/wjg.14.1268
Published online Feb 28, 2008. doi: 10.3748/wjg.14.1268
Parameter | Sequential lamivudine -INF-αtherapy | Lamivudine monotherapy | Interferon monotherapy |
Number of patients | 24 | 35 | 12 |
Sex ratio (male/female) | 21/3 | 29/6 | 9/3 |
Mean age (y) | 33 ± 6 | 32 ± 5 | 31 ± 8 |
Mean Knodell score | |||
pretreatment | 8.9 ± 3.6 | 8.2 ± 4.5 | 7.1 ± 4.0 |
post-treatment | 6.6 ± 4.0a | 5.6 ± 3.2a | 5.0 ± 2.8 |
Mean ALT level (nkat/L) | |||
Pretreatment | 3423 ± 2388 | 4390 ± 2454 | 3006 ± 1720 |
Post-treatment | 668 ± 400a | 667 ± 384a | 1686 ± 1286a |
Serum HBV DNA (log10) | |||
Pretreatment | 7.5 ± 1.3 | 7.7 ± 0.8 | 7.8 ± 1.1 |
Post-treatment | 3.8 ± 1.0a | 3.7 ± 1.2a | 5.0 ± 1.5ac |
Intrahepatic HBV DNA (log10) | |||
Pretreatment | 5.8 ± 1.2 | 6.2 ± 0.9 | 6.3 ± 0.9 |
Post-treatment | 4.7 ± 1.1a | 4.6 ± 1.5a | 5.6 ± 1.5ac |
Intrahepatic ccc DNA (log10) | |||
Pretreatment | 5.1 ± 1.0 | 5.2 ± 1.2 | 5.8 ± 1.2 |
Post-treatment | 3.4 ± 1.3a | 3.8 ± 1.1a | 5.0 ± 1.5c |
HBeAg seroconversion | |||
rate at the treatment completion | 8/21 (38.1%) | 6/32 (18.6%) | 3/12 (25%) |
Sustained virological response | |||
rate at 24 wk off treatment | 4/16 (25%) | 13/31 (41.9%) | 1/1 (100%) |
Parameter | HBeAg positive | HbeAg serocon -version | Sustained virological response | Virological flares |
Number of patients | 48 | 17 | 18 | 30 |
Mean Knodell score | ||||
Pretreatment | 8.4 ± 4.1 | 7.1 ± 4.2 | 8.0 ± 4.0 | 8.4 ± 3.9 |
Post-treatment | 6.0 ± 3.6 | 5.1 ± 3.1a | 6.1 ± 3.0 | 5.2 ± 2.7a |
Mean ALT level (nkat/L) | ||||
Pretreatment | 3206 ± 2338 | 3841 ± 2371 | 3340 ± 2638 | 4576 ± 2505 |
Post-treatment | 1018 ± 985 | 618 ± 384a | 517 ± 300 | 601 ± 400 |
24 wk off- treatment | 851 ± 200 | 380 ± 183e | ||
Serum HBV DNA (log10) | ||||
Pretreatment | 7.9 ± 0.9 | 7.5 ± 1.0 | 7.3 ± 1.3 | 7.6 ± 0.8 |
Post-treatment | 4.4 ± 1.4a | 3.0 ± 0.2ac | 3.1 ± 0.3a | 3.3 ± 0.4a |
24 wk off-treatment | 3.2 ± 0.3 | 6.1 ± 0.8ac | ||
Intrahepatic HBV DNA (log10) | ||||
Pretreatment | 6.3 ± 0.8 | 5.6 ± 1.2 | 5.9 ± 0.8 | 6.0 ± 1.1 |
Post-treatment | 5.1 ± 1.5 | 4.1 ± 0.8a | 4.5 ± 1.6 | 4.3 ± 1.0a |
Intrahepatic ccc DNA (log10) | ||||
Pretreatment | 5.5 ± 1.1 | 5.8 ± 1.0 | 4.6 ± 1.0 | 5.4 ± 0.8e |
Post-treatment | 3.9 ± 1.5 | 2.8 ± 1.3ac | 4.0 ± 0.9 | 3.8 ± 0.8a |
Parameter | HBV Genotype C | HBV Genotype B |
Number of patients | 61 | 10 |
Sex ratio (male/female) | 50/11 | 9/1 |
Number of Sequential therapy | 20 (32.8%) | 4 (40%) |
Number of Lamivudine therapy | 31 (50.8%) | 4 (40%) |
Number of Interferon therapy | 10 (16.4%) | 2 (20%) |
Mean Knodell score | ||
Pretreatment | 8.1 ± 4.1 | 5.7 ± 3.2 |
Post-treatment | 6.0 ± 3.4a | 5.4 ± 3.1 |
Mean ALT level (nkat/L) | ||
Pretreatment | 3390 ± 2438 | 2438 ± 2296 |
Post-treatment | 901 ± 918 | 551 ± 233 |
24 wk off-treatment | 1503 ± 1336 | 1987 ± 1720 |
Serum HBV DNA (log10) | ||
Pretreatment | 7.7 ± 1.2 | 7.6 ± 0.8 |
Post-treatment | 4.05 ± 1.3a | 4.9 ± 1.2a |
24 wk off-treatment | 5.1 ± 1.6 | 5.3 ± 1.3 |
Intrahepatic HBV DNA (log10) | ||
Pretreatment | 6.1 ± 0.9 | 5.6 ± 1.5 |
Post-treatment | 4.9 ± 1.4a | 4.7 ± 1.2a |
Intrahepatic ccc DNA (log10) | ||
Pretreatment | 5.6 ± 1.1 | 5.8 ± 0.5 |
Post-treatment | 3.5 ± 1.2a | 3.9 ± 1.9 |
Sustained virological response rate at | ||
24 wk off-treatment | 29.4% (15/51) | 30% (3/10) |
ALT normalization rate at | ||
24 wk off-treatment | 39.3% (24/51) | 30% (3/10) |
- Citation: Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y. Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2008; 14(8): 1268-1273
- URL: https://www.wjgnet.com/1007-9327/full/v14/i8/1268.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.1268